RATIONALE: Positive allosteric modulators of the glutamatergic alpha-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid (AMPA) receptor do not stimulate AMPA receptors directly but delay deactivation of the receptor and/or slow its desensitisation. This results in increased synaptic responses and enhanced long-term potentiation. Thus, it has been suggested that such compounds may have utility for the treatment of cognitive impairment. OBJECTIVES: The objective of the study was to investigate the effect of an AMPA positive modulator, CX691, (1) in three rodent models of learning and memory, (2) on neurochemistry in the dorsal hippocampus and medial prefrontal cortex following acute administration, and (3) on brain-derived neurotrophic factor (BDNF) messenger RNA (mRNA) expression in the rat hippocampus following acute and sub-chronic administration. RESULTS: CX691 attenuated a scopolamine-induced impairment of cued fear conditioning following acute administration (0.1 mg/kg p.o.) and a temporally induced deficit in novel object recognition following both acute (0.1 and 1.0 mg/kg p.o.) and sub-chronic (bi-daily for 7 days) administration (0.01, 0.03, 0.1 mg/kg p.o.). It also improved attentional set-shifting following sub-chronic administration (0.3 mg/kg p.o.). Acute CX691 (0.1, 0.3 and 1.0 mg/kg, p.o.) increased extracellular levels of acetylcholine in the dorsal hippocampus and medial prefrontal cortex and dopamine in the medial prefrontal cortex. Sub-chronic administration of CX691 (0.1 mg/kg, p.o.) elevated BDNF mRNA expression in both the whole and CA(1) sub-region of the hippocampus (P < 0.05). CONCLUSIONS: Collectively, these data support the pro-cognitive activity reported for AMPA receptor positive modulators and suggest that these compounds may be of benefit in treating disorders characterised by cognitive deficits such as Alzheimer's disease and schizophrenia.
RATIONALE: Positive allosteric modulators of the glutamatergic alpha-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid (AMPA) receptor do not stimulate AMPA receptors directly but delay deactivation of the receptor and/or slow its desensitisation. This results in increased synaptic responses and enhanced long-term potentiation. Thus, it has been suggested that such compounds may have utility for the treatment of cognitive impairment. OBJECTIVES: The objective of the study was to investigate the effect of an AMPA positive modulator, CX691, (1) in three rodent models of learning and memory, (2) on neurochemistry in the dorsal hippocampus and medial prefrontal cortex following acute administration, and (3) on brain-derived neurotrophic factor (BDNF) messenger RNA (mRNA) expression in the rat hippocampus following acute and sub-chronic administration. RESULTS:CX691 attenuated a scopolamine-induced impairment of cued fear conditioning following acute administration (0.1 mg/kg p.o.) and a temporally induced deficit in novel object recognition following both acute (0.1 and 1.0 mg/kg p.o.) and sub-chronic (bi-daily for 7 days) administration (0.01, 0.03, 0.1 mg/kg p.o.). It also improved attentional set-shifting following sub-chronic administration (0.3 mg/kg p.o.). Acute CX691 (0.1, 0.3 and 1.0 mg/kg, p.o.) increased extracellular levels of acetylcholine in the dorsal hippocampus and medial prefrontal cortex and dopamine in the medial prefrontal cortex. Sub-chronic administration of CX691 (0.1 mg/kg, p.o.) elevated BDNF mRNA expression in both the whole and CA(1) sub-region of the hippocampus (P < 0.05). CONCLUSIONS: Collectively, these data support the pro-cognitive activity reported for AMPA receptor positive modulators and suggest that these compounds may be of benefit in treating disorders characterised by cognitive deficits such as Alzheimer's disease and schizophrenia.
Authors: Donald C Goff; J Steven Lamberti; Andrew C Leon; Michael F Green; Alexander L Miller; Jayendra Patel; Theo Manschreck; Oliver Freudenreich; Steven A Johnson Journal: Neuropsychopharmacology Date: 2007-05-09 Impact factor: 7.853
Authors: Yann Humeau; Daniel Reisel; Alexander W Johnson; Thilo Borchardt; Vidar Jensen; Christine Gebhardt; Verena Bosch; Peter Gass; David M Bannerman; Mark A Good; Øivind Hvalby; Rolf Sprengel; Andreas Lüthi Journal: J Neurosci Date: 2007-10-10 Impact factor: 6.167
Authors: Marzena Mackowiak; Michael J O'Neill; Caroline A Hicks; David Bleakman; Phil Skolnick Journal: Neuropharmacology Date: 2002-07 Impact factor: 5.250
Authors: Michael Michaelides; Javier Pascau; Juan-Domingo Gispert; Foteini Delis; David K Grandy; Gene-Jack Wang; Manuel Desco; Marcelo Rubinstein; Nora D Volkow; Panayotis K Thanos Journal: Eur J Neurosci Date: 2010-07-16 Impact factor: 3.386
Authors: Simon E Ward; Mark H Harries; Laura Aldegheri; Andrea M Bradford; Elisa Ballini; Lee Dawson; Laurent Lacroix; Joanne Pardoe; Kathryn Starr; Annette Weil; Kerry Waters; John R Atack; Marie Woolley Journal: J Psychopharmacol Date: 2019-11-26 Impact factor: 4.153
Authors: Simon E Ward; Paul Beswick; Novella Calcinaghi; Lee A Dawson; Jane Gartlon; Francesca Graziani; Declan N C Jones; Laurent Lacroix; M H Selina Mok; Beatrice Oliosi; Joanne Pardoe; Kathryn Starr; Marie L Woolley; Mark H Harries Journal: Br J Pharmacol Date: 2017-01-31 Impact factor: 8.739
Authors: Roberta Bursi; Gul Erdemli; Robert Campbell; Matthew M Hutmacher; Thomas Kerbusch; David Spanswick; Ross Jeggo; Kari R Nations; Peter Dogterom; Jacques Schipper; Mohammed Shahid Journal: Psychopharmacology (Berl) Date: 2011-06-07 Impact factor: 4.530
Authors: Bashkim Kadriu; Laura Musazzi; Jenessa N Johnston; Lisa E Kalynchuk; Hector J Caruncho; Maurizio Popoli; Carlos A Zarate Journal: Drug Discov Today Date: 2021-08-03 Impact factor: 8.369